DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

Abstract The CCTG PA.7 study was a randomized phase II trial comparing chemotherapy with and without dual immune checkpoint inhibition in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). In follow-up to the published primary results of the trial, the analysis herein focused on long...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Daniel J. Renouf, James T. Topham, Jonathan M. Loree, David F. Schaeffer, Jennifer J. Knox, Petr Kavan, Derek Jonker, Stephen Welch, Felix Couture, Frederic Lemay, Mustapha Tehfe, Mohammed Harb, Nathalie Aucoin, Yoo-Joung Ko, Patricia A. Tang, Ravi Ramjeesingh, Brandon M. Meyers, Christina A. Kim, Pan Du, Shidong Jia, Joanna M. Karasinska, Sharlene Gill, Dongsheng Tu, Chris J. O’Callaghan
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2026-03-01
Serija:	Nature Communications
Online dostop:	https://doi.org/10.1038/s41467-026-70120-z
Oznake:	Označite Brez oznak, prvi označite!